VANCOUVER, British Columbia and BOSTON, Jan. 07, 2025 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced that the company will present at the 43rd Annual J.P. Morgan Healthcare Conference taking place in San Francisco, CA from January 13-16, 2025.
Company Presentation Details:
| Date: | Monday, January 13, 2025 |
| Time: | 9:45-10:25 AM Pacific Time (12:45-1:25 PM Eastern Time) |
| Webcast: | Register here |
| Presenter: | Ian Mortimer, President and Chief Executive Officer, Xenon Pharmaceuticals |
A live audio webcast of the company presentation will be available on the “Investors” section of Xenon’s website and posted for replay following the event. The above listed dates and times are subject to change.
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics. We are advancing an ion channel product portfolio to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. For more information, please visit www.xenon-pharma.com.
“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.
Contacts:
For Investors:
Chad Fugere
Vice President, Investor Relations
(857) 675-7275
investors@xenon-pharma.com
For Media:
Colleen Alabiso
Senior Vice President, Corporate Affairs
(617) 671-9238
media@xenon-pharma.com
The VENTANA DP 600 slide scanner, part of Roche's Digital Pathology Dx system, is now…
TestoPrime is a top rated, all natural testosterone booster for men in their 40's and…
Lipozem: We Tested Lipozem Supplement - Here Is Our Honest Review NEW YORK CITY, NY…
Proenkephalin A 119-159 (penKid) demonstrates potential as a predictor for successful discontinuation of continuous renal…
Ad hoc announcement pursuant to Art. 53 LR Revenue Growth: Full-year 2024 revenue of €265.7…
BEIJING, Jan. 8, 2025 /PRNewswire/ -- In a recent achievement, DP Technology's hit discovery platform RiDYMO® has…